AzTrials
AzTrials

Second Trimester AbortionNCT04501809

Second Trimester Pregnancy Termination in Women With Previous Caesarean Sections

A study testing compare misoprostol with combined oxytocin and cervical foly catheter in people with Second Trimester Abortion, run by Zagazig University at 2 sites in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

it is a randomized controlled trial comparing the safety and efficacy of Vaginal Misoprostol versus combined Intracervical Foley's Catheter and Oxytocin Infusion for Second Trimester Pregnancy Termination. Read more about this study

Who is it for?
Ages 17 to 42 years, women only
Conditions the study is for
Second Trimester Abortion
What is being tested?
compare misoprostol with combined oxytocin and cervical foly catheter
Could I receive a placebo?
No, everyone receives an active treatment
How many people
158 participants
Where
2 sitesEgypt
Study dates
15 Jul 2020to Jan 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 17 to 42 years
  • Women only
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • women indicated for termination of pregnancy between 14weeks-23 weeks and 6 days of gestation
  • singleton pregnancy
  • one or multiple cesarean delivery.

Who cannot join

  • bleeding disorders
  • chorioamnionitis
  • low-lying placenta
  • history of rupture uterus
  • history of myomectomy
  • contraindication to misoprostol
  • latex allergy.

Trial locations and contacts

2 sites in 1 country.

Egypt2 sites, 2 recruiting
  • Zagazig University

    Zagazig, East, 44511

    tolba ewida street 2 zagazig, 2, 002/01004132040, basem@zu.edu.eg

    basemhamedobgyne@yahoo.com.sg

    Recruiting
  • Tolba Ewida Street

    Zagazig, Sharqia Province, 44511

    basem hamed, 01004132040, basem@zu.edu.eg

    Recruiting

Other trials in Egypt

About this study

Official title: Vaginal Misoprostol Versus Combined Intracervical Foley's Catheter and Oxytocin Infusion for Second Trimester Pregnancy Termination in Women With Previous Caesarean Sections

it is a randomized controlled trial comparing the safety and efficacy of Vaginal Misoprostol versus combined Intracervical Foley's Catheter and Oxytocin Infusion for Second Trimester Pregnancy Termination. the patients will be sorted into 2 groups, Group I (Misoprostol group): seventy-nine patients and Group II (Combined group): seventy- nine patients. safety and efficacy of the procedure will be followed up and documented.

Read the detailed description

Design: prospective randomized controlled trial Sitting: department of Obstetrics and Gynecology Faculty of Medicine, Zagazig University, Zagazig, Egypt Sample size calculation: thoroughly reviewing the use of vaginal misoprostol and intracervical Foleys catheter alone or in combination for mid trimester pregnancy termination, Rezk et al 2014 showed that the percentage of complications "fever and diarrhea" in the first group (misoprostol) was 30 % versus complications in the second group (intra cervical Foleys group)" cervical laceration "was 13.3 %. Therefore, at confidence level 95% and power 80%, using Epi info 7 the Sample size will be one hundred fifty-eight (158) patients.

Study participants: the study will include women indicated for termination of pregnancy between 14weeks-23 weeks and 6 days of gestation. The investigators will involve patients with a singleton pregnancy with one or multiple cesarean delivery. The investigators will exclude all patients with critical co-morbidities: bleeding disorders, chorioamnionitis, low-lying placenta, rupture uterus, myomectomy and contraindication to misoprostol or latex allergy. All women will undergo history taking, general examination, and local assessment for the cervix. Departmental US to confirm the diagnosis and indication for termination and position of the placenta. Blood tests will be done including blood group, full blood count matching, Antibodies screening and viral markers.

Randomization: After meeting eligibility criteria all participants will be counseled to the clinical trial. A signed documented consent form will be attached to their medical records. The patients will be sorted into two groups using a computerized random number generator in a sequence of sealed, numbered opaque envelopes, with a 1:1randomization ratio.

Group I (Misoprostol group): seventy-nine patients will receive a loading dose of moistened misoprostol tablets (cytotec pfizer 400 mg) inserted vaginally and it will be followed by maintenance dose (200 mg) after six hours and repeated every 4 hours till the start of effective uterine contraction with maximum five doses in 24 hours duration .

Group II (Combined group): seventy- nine patients will get intracervical Foleys Catheter insertion .Exposure of the cervix by means of a sterile speculum, a 16F Foley catheter will be introduced into the cervical canal to induce cervical ripping. The catheter will be fixed through inflation of the balloon with 30 milliliters of sterile solution when the catheter will be beyond the internal cervical os. Slight traction of the catheter will be exerted through tapping it to the inner thigh. After six hours of Foleys catheter fixation, The investigators will start infusion of 10 IU of oxytocin on 500 ml ringer lactate by rate 125 ml\hr followed by one hour rest to allow diuresis. Increased gradually of oxytocin dose by 5IU each time until achieving regular uterine contraction, maximum five doses in twenty -four hours duration. Therefore the maximum dose of oxytocin 100 IU over 24 hrs duration to avoid water intoxication.

Failed induction of abortion is considered if no fetal expulsion occurred within twenty for hours from the use of primary method of termination. The Demographic data and serial clinical monitoring will be recorded by the assigned on duty registrar.

Being tested
compare misoprostol with combined oxytocin and cervical foly catheter
Keywords
abortion

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • compare misoprostol with combined oxytocin and cervical foly catheterProcedure or surgery

    we will compare using misoprostol alone in one group with oxytocin and cervical catheter in the other group

Study groups in NCT04501809
Study groupRoleWhat they receive
Group I (Misoprostol group):Active comparatorseventy-nine patients will receive a loading dose of moistened misoprostol tablets ( Cytotec pfizer 400 mg) inserted vaginally and it will be followed by maintenance dose (200 mg) after six hours and repeated every 4 hours till the start of effective uterine contraction with maximum five doses in 24 hours duration .
Receives: Procedure: compare misoprostol with combined oxytocin and cervical foly catheter
Group II (Combined group):Active comparatorseventy- nine patients will get intracervical Foleys Catheter insertion .a 16F (french units) Foley catheter will be introduced into the cervical canal to induce cervical ripping. The catheter will be fixed through inflation of the balloon with 30 milliliters of sterile solution when the catheter will be beyond the internal cervical os. After six hours of Foleys catheter fixation, we will start infusion of 10 international units (IU) of oxytocin on 500 ml ringer lactate by rate 125 ml\hr followed by one hour rest to allow diuresis. Increased gradually of oxytocin dose by 5 IU each time until achieving regular uterine contraction, maximum five doses in twenty -four hours duration.
Receives: Procedure: compare misoprostol with combined oxytocin and cervical foly catheter

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. time to cervical dilatation in hours

    time between starting the medications and the real cervical dilatation

    Measured: 24 hours

  2. induction abortion interval in hours

    time between induction of abortion and expulsion of the products of conception

    Measured: 48 hours

  3. need for surgical evacuation

    some cases may be presented with retained products of conception with the need for surgical evacuation of the uterus

    Measured: 48 hours

Secondary outcomes (4)
  1. sever hemorrhage

    comparing the prevalence of severe hemorrhage by postoperative hemoglobin percent in both groups.

    Measured: 48 hours

  2. patients satisfaction

    by patient written questionnaire about patient discomfort.

    Measured: 72 hours

  3. post-abortive infection

    Number of participants with post-abortive infection is predicted by post-abortive C reactive protein (CRP) level

    Measured: 7 days

  4. rupture uterus

    comparing the incidence of rupture uterus (clinically by sever abdominal pain and loss of uterine contractions and presence of free fluid by ultrasound) in both groups

    Measured: 48 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Aug 2020
  2. Study start15 Jul 2020
  3. Primary completionJan 2021 (estimated)
  4. Study completionJan 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
158 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04501809
Sponsor's protocol ID
6276/14-7-2020
Status last verified
Aug 2020
First submitted
15 Jul 2020
Last updated
6 Aug 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Elasy AN, Ibrahem MA, Elhawy LL, Hamed BM. Vaginal misoprostol versus combined intracervical foley's catheter and oxytocin infusion for second trimester pregnancy termination in women with previous caesarean sections: a randomised control trial. J Obstet Gynaecol. 2022 Oct;42(7):2962-2969. doi: 10.1080/01443615.2022.2118572. Epub 2022 Sep 23.

    PubMed 36149628

Questions about this trial

What is this clinical trial studying?

A study testing compare misoprostol with combined oxytocin and cervical foly catheter in people with Second Trimester Abortion, run by Zagazig University at 2 sites in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

time to cervical dilatation in hours (time frame: 24 hours). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04501809, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in